Literature DB >> 9167998

During development, 17alpha-estradiol is a potent estrogen and carcinogen.

R A Hajek1, A D Robertson, D A Johnston, N T Van, R K Tcholakian, L A Wagner, C J Conti, M L Meistrich, N Contreras, C L Edwards, L A Jones.   

Abstract

Neonatal administration of estradiol-17beta (E2-17beta) increases the nuclear DNA content in the mouse reproductive tract. Similar responses have been demonstrated for synthetic estrogens such as diethylstilbestrol. One of the questions raised regarding environmental estrogens such as organochlorines is whether they are potent enough to result in abnormal changes such as those demonstrated by both natural and synthetic estrogens. To test this hypothesis, female BALB/c mice were treated neonatally (days 1-5) with either E2-17beta or estradiol-17alpha (E2-17alpha), an inactive stereoisomer in adult reproductive tissues. We also proposed whether neonatal administration of (E2-17alpha) was tumorigenic and whether the effects were age dependent. To answer these questions, one set each of 10 day-old treated and control mice received short-term secondary administration of E2-17beta, E2-17alpha, or cholesterol. Cervicovaginal tracts from intact BALB/c mice were examined histologically and by flow cytometry at 70 days of age and by histology alone at 18 to 22 months of age. The results include several important findings: a) like E2-17beta, neonatal E2-17alpha treatment induced persistent vaginal cornification, hypospadias, vaginal concretions, and hyperproliferation in nearly 100% of the animals regardless of the secondary treatment for most groups; b) neonatal E2-17alpha treatment increased the nuclear DNA content of cervicovaginal epithelium at one-half both the level (mean DNA index of 1.02 vs 1.04) and incidence (22 vs 46% of the animals) of E2-17beta; c) short-term secondary treatment with E2-17alpha, unlike E2-17beta, did not significantly augment the increase in DNA content (13% for E2-17alpha vs 37 and 56% for control and E2-17beta, respectively); and d) neonatal administration with E2-17alpha induced adenosquamous tumors in the reproductive tract in 25% of the animals. Therefore, the biological effects (estrogenic potency) of E2-17alpha may be age dependent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9167998      PMCID: PMC1469906          DOI: 10.1289/ehp.97105s3577

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  26 in total

1.  2-Fluoroestradiol. Separation of estrogenicity from carcinogenicity.

Authors:  J G Liehr
Journal:  Mol Pharmacol       Date:  1983-03       Impact factor: 4.436

2.  Role of chemically induced mutagenic events in neoplastic transformation of Syrian hamster embryo cells.

Authors:  J C Barrett; T W Hesterberg; M Oshimura; T Tsutsui
Journal:  Carcinog Compr Surv       Date:  1985

3.  Effects of estradiol-17 alpha on nuclear occupancy of the estrogen receptor, stimulation of nuclear type II sites and uterine growth.

Authors:  J H Clark; M Williams; S Upchurch; H Eriksson; E Helton; B M Markaverich
Journal:  J Steroid Biochem       Date:  1982-02       Impact factor: 4.292

4.  Estrogen 2- and 4-hydroxylase activity, catechol estrogen formation, and implications for estrogen carcinogenesis in the hamster kidney.

Authors:  S A Li; J K Klicka; J J Li
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

5.  Regulation of prolactin production and cell growth by estradiol: difference in sensitivity to estradiol occurs at level of messenger ribonucleic acid accumulation.

Authors:  J F Amara; C Van Itallie; P S Dannies
Journal:  Endocrinology       Date:  1987-01       Impact factor: 4.736

6.  Progesterone metabolism by cultured Sertoli cells.

Authors:  R K Tcholakian; A Steinberger
Journal:  Endocrinology       Date:  1978-10       Impact factor: 4.736

7.  Relative carcinogenic activity of various synthetic and natural estrogens in the Syrian hamster kidney.

Authors:  J J Li; S A Li; J K Klicka; J A Parsons; L K Lam
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

8.  Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.

Authors:  R R Reddel; R L Sutherland
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

9.  Mitotic inhibition and aneuploidy induction by naturally occurring and synthetic estrogens in Chinese hamster cells in vitro.

Authors:  W J Wheeler; L M Cherry; T Downs; T C Hsu
Journal:  Mutat Res       Date:  1986-07       Impact factor: 2.433

Review 10.  Effects of estrogenic chemicals on development.

Authors:  L A Jones; R A Hajek
Journal:  Environ Health Perspect       Date:  1995-10       Impact factor: 9.031

View more
  9 in total

1.  10β,17α-Dihydroxyestra-1,4-dien-3-one: A Bioprecursor Prodrug Preferentially Producing 17α-Estradiol in the Brain for Targeted Neurotherapy.

Authors:  Katalin Prokai-Tatrai; Vien Nguyen; Laszlo Prokai
Journal:  ACS Chem Neurosci       Date:  2018-06-05       Impact factor: 4.418

2.  Simultaneous Measurement of 17β-Estradiol, 17α-Estradiol and Estrone by GC-Isotope Dilution MS/MS.

Authors:  Katalin Prokai-Tatrai; Darius Bonds; Laszlo Prokai
Journal:  Chromatographia       Date:  2010-02       Impact factor: 2.044

3.  Naturally occurring osteoarthritis in male mice with an extended lifespan.

Authors:  Dave Ewart; Lindsey Harper; Amy Gravely; Richard A Miller; Cathy S Carlson; Richard F Loeser
Journal:  Connect Tissue Res       Date:  2019-09-18       Impact factor: 3.417

4.  ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury.

Authors:  C Dominique Toran-Allerand; Xiaoping Guan; Neil J MacLusky; Tamas L Horvath; Sabrina Diano; Meharvan Singh; E Sander Connolly; Imam S Nethrapalli; Alexander A Tinnikov
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

5.  It's time to rethink dose: the case for combining cancer and birth and developmental defects.

Authors:  D Axelrod; D L Davis; R A Hajek; L A Jones
Journal:  Environ Health Perspect       Date:  2001-06       Impact factor: 9.031

6.  Evidence that 17alpha-estradiol is biologically active in the uterine tissue: antiuterotonic and antiuterotrophic action.

Authors:  Mercedes Perusquía; Erika Navarrete
Journal:  Reprod Biol Endocrinol       Date:  2005-07-21       Impact factor: 5.211

Review 7.  Evaluating the effects of endocrine disruptors on endocrine function during development.

Authors:  R Bigsby; R E Chapin; G P Daston; B J Davis; J Gorski; L E Gray; K L Howdeshell; R T Zoeller; F S vom Saal
Journal:  Environ Health Perspect       Date:  1999-08       Impact factor: 9.031

8.  Is the incidence of hypospadias increasing? Analysis of Finnish hospital discharge data 1970-1994.

Authors:  M Aho; A M Koivisto; T L Tammela; A Auvinen
Journal:  Environ Health Perspect       Date:  2000-05       Impact factor: 9.031

9.  Long-term effects of neonatal exposure to hydroxylated polychlorinated biphenyls in the BALB/cCrgl mouse.

Authors:  Jeanelle M Martinez; L Clifton Stephens; Lovell A Jones
Journal:  Environ Health Perspect       Date:  2005-08       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.